Gefitinib, EGFR tyrosine kinase inhibitor (ab142052)

Overview

  • Product name

    Gefitinib, EGFR tyrosine kinase inhibitor
  • Description

    Orally active, potent, selective EGFR tyrosine kinase inhibitor
  • Alternative names

    • Iressa™
    • ZD 1839
    • ZD1839
  • Biological description

    Orally active, potent, selective EGFR (Epidermal growth factor receptor) tyrosine kinase inhibitor (IC50 = 33 nM). Inhibits EGF-stimulated EGFR autophosphorylation and inhibits tumor growth in vivo. Enhances efficacy of cytotoxic agents. Inhibits growth factor production and angiogenesis. Clinically useful anticancer agent.

  • Purity

    > 98%
  • CAS Number

    184475-35-2
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
  • Molecular weight

    446.90
  • Molecular formula

    C22H24ClFN4O3
  • PubChem identifier

    123631
  • Storage instructions

    Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
  • Solubility overview

    Soluble in DMSO to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
  • Source

    Synthetic

References

This product has been referenced in:

  • McKillop D  et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4:641-9 (2005). Read more (PubMed: 15827338) »
  • Wakeling AE  et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-54 (2002). Read more (PubMed: 12384534) »
  • Ciardiello F  et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-65 (2001). Read more (PubMed: 11350918) »
  • Ciardiello F  et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-63 (2000). Read more (PubMed: 10815932) »
  • Baselga J & Averbuch SD ZD1839 ('Iressa') as an anticancer agent. Drugs 60 Suppl 1:33-40; discussion 41-2 (2000). Read more (PubMed: 11129170) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142052.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up